CTRI/2023/03/050799
Not Yet Recruiting
N/A
Evaluation of the Effects of Dapaglifozin (sglt-2 inhibitor) on Hepatic Steatosis and fibrosis using Anthropometric, Biochemical and Radiological indices in patients with type 2 Diabetes Mellitus and Non Alcoholic fatty liver disease
Department of medicine Jawaharlal Nehru medical college and hospital AMU Aligarh0 sites0 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of medicine Jawaharlal Nehru medical college and hospital AMU Aligarh
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnosed type 2 DM patients on standard treatment for diabetes whether be it Insulin or oral hypoglycemic agents except all SGLT2 Inhibitors
- •2\. Patients diagnosed with NAFLD made on the basis of history of low daily alcohol intake ( \< 30 g for men and \< 20 g for women), liver biochemistry, presence of fatty liver on ultrasonography and transient elastography.
- •3\. Patients giving informed consent
Exclusion Criteria
- •1\. Patients with other causes of chronic liver disease like chronic viral hepatitis, autoimmune hepatitis, excessive alcoholic consumption, drug\-induced liver injury, biliary tract disease, decompensated liver cirrhosis, hepatocellular carcinoma, history of diabetic ketoacidosis
- •2\. Patients with co\-administration of medications that may affect liver function tests (such as NSAIDS, Vitamin E, pioglitazone, saroglitazar, statin, and TZDs)
- •3\. Presence of severe comorbidities such as CAD, CHF, CKD, COPD, pyelonephritis and chronic UTI
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Impact of treatment with Dapagliflozin in type 1 diabetic patientsEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
Completed
Phase 1
Dapagliflozin Effects on HypoglycemiaType1 Diabetes MellitusNCT03704818University of California, San Diego22
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003897-41-PLAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003897-41-BGAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.EUCTR2016-003897-41-SEAstraZeneca AB4,500